Background-Long-term patency of conventional synthetic grafts is unsatisfactory below a 6-mm internal diameter.
S mall-diameter prostheses are needed for cardiac and peripheral revascularization procedures. Autologous arterial and venous grafts are by far the best options as small-diameter bypass grafts 1 ; however, they cannot be used in all patients because of several limitations (ie, vasospasm, limited length, poor quality, and prior use). Homografts degenerate fast in the arterial circulation and have been used very selectively. 2 Conventional vascular prostheses such as expanded polytetrafluoroethylene (ePTFE) and polyethyleneterephtalate (Dacron) grafts have been used clinically for decades, but they are prone to thrombosis and intimal hyperplasia. 3 Their long-term results are unsatisfactory below 6 mm of internal diameter. 3, 4 
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To date, several biodegradable polymers such as polyglycolic acid, 5, 6 polylactic acid, polydioxanone, [7] [8] [9] and polyurethane 10 have been investigated to serve as vascular scaffolds. The main principle is to create a temporary scaffold through which in vivo tissue ingrowth can replace the prosthesis, leaving a complete biological vascular conduit in due time. 11 In addition, such scaffolds should be biocompatible, compliant, easily processable, economical, and shelf ready for use as a vascular prosthesis. 4 So far, no biodegradable smalldiameter vascular prosthesis made of such biodegradable polymers has reached clinical use in the arterial circulation.
Poly(⑀-caprolactone) (PCL) is a well-known biodegradable polymer with longer degradation time compared with other polymers. [12] [13] [14] To date, it has been used clinically as a long-term contraceptive device (Capronor, Research Triangle Inst, Durham, NC) and for meniscus 15 and bone 16 reconstruction in animals. Recently, some groups have published their in vitro results with 3-dimensional vascular scaffolds made of PCL. Vaz 17 fabricated 2-mm-internal diameter grafts with 2 layers of nanofibers: PCL on the luminal side and polylactic acid on the adventitial side. Pham et al 18 used the same approach and fabricated bilayer grafts with PCL microfibers on the luminal side and PCL nanofibers on the adventitial side. Both groups used electrospinning to produce their fiber-based scaffolds. This technique allows the preparation of an extracellular matrix-mimicking structure, which should be beneficial for in situ tissue regeneration. However, they focused mainly on characterization and optimization of the production technique, and no in vivo results have been published.
The results of our in vitro optimization process, including the initial in vivo feasibility, have recently been published. 19 In the present study, our aims were to prepare biodegradable PCL-nanofiber grafts with optimal mechanical properties and to evaluate their in vivo healing and degradation characteristics in the rat arterial circulation at up to 6 months compared with conventional ePTFE vascular grafts.
Methods

Preparation of Vascular Grafts
Grafts (2-mm internal diameter, 13-mm length) made of PCL (M n ϭ80 000 g/mol, M w ϭ120 000 g/mol) were prepared by electrospinning as previously described in detail. 19 Briefly, these grafts were obtained by use of a 15% (wt/vol) PCL solution in CHCl 3 / EtOH (7:3 vol:vol) and 6 minutes of spinning time, 12-mL/h flow rate, 20-cm tip collector distance, and 20-kV voltage. All grafts were free of beads 19 and had a mean fiber diameter of 1.90 m, a tensile stress of 4.8 MPa, and a tensile strain of 600% after sterilization (gamma radiation, 25 kGy). The absence of residual solvent was confirmed in 3 sterile ready-to-implant grafts by the head-spacecoupled GC detection technique. Commercially available ePTFE grafts (Atrium, 30-m thru-pore, 2-mm internal diameter, 13 mm long) sterilized by ethylene oxide served as controls.
In Vivo Implantations, Follow-Up, and Sacrifice
Thirty male Sprague-Dawley rats (354 to 450 g) were operated on under isoflurane 2% mask anesthesia after induction with isoflurane 5%. The abdomen was shaved; a midline laparotomy incision was performed; and the infrarenal abdominal aorta was isolated by blunt and sharp dissection. After proximal and distal clamping, just below the renal arteries and above the aortoiliac bifurcation, a 1-cm segment of the abdominal aorta was resected in a bevelled way. Either PCL (nϭ15) or ePTFE (nϭ15) grafts were implanted randomly with 10-0 nylon interrupted sutures under sterile conditions using an operative microscope of ϫ25 magnification. The abdominal cavity and skin were closed, and animals recovered from anesthesia and were kept in separate cages with normal food and water ad libitum. Rats were followed up for 3, 6, 12, 18, and 24 weeks (nϭ3 for each time point in each group). At the conclusion of the study period, all rats were anesthetized by intraperitoneal thiopental injection (40 mg/kg), and the left carotid artery was cannulated (24G intravenous cannula). Digital subtraction angiography (General Electric Cardiac Series, 9800, Salt Lake City, Utah) was performed in vivo, followed by explantation of the infrarenal segment of the abdominal aorta, including the implanted graft, and the animal was killed by pentobarbital overdose. The North American Symptomatic Carotid Endarterectomy Trial formula was used to calculate the degree of stenosis in the grafts. The experimental protocol was approved by the Animal Experiments Ethics Committee of the University of Geneva (protocol 06/52) and the Veterinary Office of State of Geneva (Switzerland; No. 1081/3232/11) and carried out in conformance with the Guide for Care and Use of the Laboratory Animals (National Research Council, Washington, DC: National Academy Press; 1996).
Histological and Quantitative Analyses
For histological investigations, explanted grafts with both anastomoses were fixed in 4% formaldehyde for 24 hours, cut into 2 longitudinal halves, and then embedded into paraffin. Histological sections (4 m) were stained with hematoxylin and eosin (H&E), Miller and Masson for elastin fibers and collagen deposition, and anti-CD31 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, Calif; PECAM-1 [M-20]) for endothelial cells and neoangiogenesis. Slides were also analyzed quantitatively by computed histomor-phometry with a Leitz Medilx (Leica, Nussloch, Germany) motorized microscope, a Sony 3CCD color video camera, and Leica Q-win software, standard version Y2.3 for image analysis. Endothelial coverage was defined as the length of endothelial cell layer on the luminal surface and was expressed as the percentage of total graft length. Neointima formation, defined as the area between the endothelial layer and luminal surface of the prosthesis, was calculated per unit length of neointima (m 2 /m). Transmural cellular ingrowth was defined as the percentage of graft area penetrated densely by host cells from the adventitial tissue toward the luminal surface.
In Vivo Degradation Analysis of PCL Grafts
In vivo degradation of implanted PCL-based vascular grafts was assessed by molecular weight (M n and (M w ) analyses of explanted grafts. Molecular weight was measured by size exclusion chromatography with Waters equipment fitted with coupled Waters Styragel HR4 and HR3 columns as the stationary phase, tetrahydrofuran at 1-cm 3 /min flow rate as the mobile phase, and a Waters 410 refractometer as the detector. Typically, a small piece of fixed prosthesis was cut and residual surrounding tissues were removed with a surgical blade. PCL graft samples were then cut into very fine pieces dissolved in tetrahydrofuran and submitted to sonication for 30 minutes. The supernatant was filtered on a 0.20-m Albet. Solid residues were further extracted in chloroform (CHCl 3 ), submitted to sonication for 30 minutes, and distilled off before tetrahydrofuran addition, filtration, and injection. Each sample was then injected in duplicate in both tetrahydrofuran and CHCl 3 . Outliers were eliminated using the Huber method in Minitab Statistical Software 15 (Minitab Inc), and V O n and (V O w are given as the mean and SEM of 12 measurements with respect to polystyrene standards.
Statistical Analysis
Statistical tests were performed with SPSS (version 16.0; SPSS Inc, Chicago, Ill). Results are expressed as meanϮSEM for continuous variables. The unpaired t test was used to compare nonparametric values. The level of significance was set at PϽ0.05.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Animal Survival and Digital Subtraction Angiography Results
Sterile PCL grafts could be implanted easily into the rats using standard microsurgical techniques. All grafts were implanted by one surgeon (E.P.). Aortic clamp time was not different between the 2 groups (67.9Ϯ1.4 minutes for the PCL group, 72.1Ϯ3.5 minutes for the ePTFE group; Pϭ0.27). No significant bleeding was observed in either group. All animals survived until the end of follow-up, and all grafts were patent in both groups (Figure 1 ). Digital subtraction angiography revealed no significant stenosis in the PCL group ( Figure 1A ) but showed stenotic lesions in the midgraft region of 1 graft at 18 weeks (40%) and of another graft at 24 weeks (50%) in the ePTFE group ( Figure 1C ). No aneurysmal dilatation was found in either group.
Morphometry Analysis
Luminal endothelial coverage was longer in PCL grafts at all time points (Figure 2) . Neointima formation increased gradually up to 12 weeks in the PCL group and reached a steady state after 3 months. Conversely, neointima formation was less pronounced but showed a persistent increase in the ePTFE group up to 24 weeks (Figure 3 ). Fifty percent of the graft body was infiltrated by macrophages at 12 weeks in the PCL group, and this infiltration showed a tendency to increase at 24 weeks. However, ePTFE grafts were not infiltrated by macrophages, so a calculation could not be performed (Figure 4 ).
Molecular Weight Analysis for Degradation
Degradation analysis of the PCL prostheses revealed gradual loss of 20% for M w and 22% for M n at up to 24 weeks after implantation ( Figure 5 ).
Histological Degradation and Healing of PCL Grafts
Histological analysis of PCL grafts revealed a rapid endothelialization of the luminal part of the graft, spreading from adjacent native aorta toward the graft body with a confluent monolayer of endothelial cells at 12 weeks ( Figure 6A and 6B). At the same time, we found a rapid and homogeneous colonization of the graft material by host cells consisting mostly of fibroblasts (the Table) . No sign was seen of chronic inflammation. On the outer part of the graft, at the interface with the surrounding connective tissue, we found a giant cell reaction accompanied by macrophages. The degradation process triggered mainly by cellular infiltrates also existed on the outer part of the graft body, covering 50% to 60% of the graft body after 12 weeks ( Figure 6A and 6C ). Furthermore, some foci of degradation by macrophages were also found beneath the endothelium. Fibroblast density increased slightly with time and was accompanied by collagen deposition (Figure 6B and 6D). We also observed neocapillary formation in the graft body starting at 3 weeks and increasing with time ( Figure  6C ). Five to 7 layers of spindle-shaped cells and elastin fibers beneath the endothelium forming a neointima were observed after 3 weeks ( Figure 6E ). With time, this neointima formation covered 60% to 70% of the luminal surface of the graft without any increase in thickness containing elastin fibers ( Figure 6F ). However, as of 6 weeks of implantation, a basophilic matrix containing round chondrocytes with lacunae appeared in some of the neointimal regions and was defined as chondroid metaplasia ( Figure 7A ). At 12 weeks, this chondroid metaplasia started to disappear ( Figure 7B ), and residual calcifications were found at 24 weeks ( Figure  7C ). During the same period, spindle-shaped cells in the neointima were replaced by collagen accumulation.
Histological Healing Characteristics of ePTFE Grafts
Histological analysis of ePTFE grafts showed a delayed endothelialization, which was still incomplete at 24 weeks ( Figure 8A and 8B ). Very few fibroblasts had infiltrated the graft body at 3 weeks with no significant increase up to 24 weeks, no macrophage or giant cell reaction was found in the perigraft area, and a trace amount of neocapillary formation was observed around the ePTFE graft (the Table) . However, we observed marked and inhomogeneous neointima formation with a steady increase in time in this group during the follow-up without any chondroid metaplasia formation ( Figure 8C and 8D) but some calcific deposits near the anastomoses (Figure 8A) . At 18 and 24 weeks, 2 ePTFE grafts had stenotic neointima formation (40% to 50%).
Miller and Masson staining revealed some collagen deposits in the ePTFE graft with sparse elastin fibers. These elastin fibers were observed in the neointima after 6 weeks and were then replaced by collagen at 24 weeks, similar to the PCL group ( Figure 8D ).
Discussion
During the last 2 decades, biodegradable materials have been a major interest in medical applications. 12, 20 The biostable materials have been replaced gradually by biodegradable materials in the field of tissue engineering. Among biodegradable polymers, polyglycolic acid, polylactic acid, polydioxanone, and PCL have been of special interest to many researchers because of their biocompatibility, wide range of mechanical properties, and biodegradation period, which make them suitable for use in the medical and pharmaceutical fields. Electrospun microfiber and nanofiber scaffolds made of such biodegradable polymers may serve as vascular grafts for tissue engineering applications because they have small pores, high porosity, high surface area, and small fiber sizes comparable to extracellular matrix of human tissues. Our previous experience with polydioxanone and polydioxanonepolylactic acid electrospun vascular grafts provided unsatisfactory results 12 weeks after implantation in the rat arterial circulation, showing significant aneurysmal dilatation caused by premature loss of strength, 21 a major cause of graft failure with degradable polymers. 22 PCL, a commercially available polyester with a slower degradation rate, is also well known for its good mechanical properties. 12 In our series, PCL grafts showed no aneurysmal dilatation at up to 6 months of follow-up, providing 100% patency rate. Premature structural deformities resulting from early degradation of the graft material seem not to be an issue for our electrospun PCL grafts because they keep their strength and prevent any aneurysm formation during the first 6 months despite the degradation of PCL chains with a molecular weight loss of Ϸ20%.
Endothelial coverage of the luminal surface, transmural cellular infiltration, and formation of neocapillaries in the graft body are the major graft healing characteristics. Additionally, degradation of graft material is an important issue for biodegradable vascular grafts. 13 Early endothelialization of the luminal surface without excess neointima formation, enhanced cellular ingrowth, and angiogenesis into the graft Chondroid metaplasia present at 6, 12, and 18 wk in the neointima; regression of chondroid metaplasia at 24 wk, which is replaced by calcification material without any inflammatory reaction potentially lead to increased biocompatibility of the implanted material and eventually better patency rates. Thus, we aimed to focus on healing of electrospun PCL vascular grafts under physiological circumstances. Moreover, ePTFE grafts are very inert, hindering graft-host interactions and graft healing and eventually leading to early graft failure. In our series, ePTFE grafts showed very poor healing compared with PCL grafts. We found that 97% of the luminal surface of PCL grafts was covered by endothelium 6 weeks after the implantation, and confluent endothelial coverage was achieved at 12 weeks.
Endothelialization of PCL grafts was significantly faster and better than that of ePTFE grafts in the follow-up. Neointima formation in the PCL group was homogeneous and leveled off 18 weeks after implantation. We speculate that this may be a consequence of the regulatory role of confluent endothelium. 23 Conversely, the ePTFE group showed incomplete endothelial coverage accompanied by a persistent increase in neointima formation with a nonhomogeneous pattern, creating stenotic lesions in 1 animal at 18 and in another at 24 weeks. Degradation of PCL occurs mainly by nonenzymatic random hydrolytic cleavage of ester linkage. 24 Enzymatic degradation by lipases may also play a role to some extent, 25 but this enzyme has not been demonstrated in humans. At the latest stages of in vivo degradation, after the fragmentation of PCL chain into low-molecular-weight fragments, intracellular degradation can take place by phagocytosis. 26 This degradation process is faster in vivo than it is in vitro. 13, 20 Bölgen et al 20 implanted PCL patches (M n ϭ51 200 g/mol, M w ϭ84 400 g/mol) subcutaneously into rats, evaluated the degradation of material with time, and demonstrated a 30% reduction in molecular weight after 3 months. In our study, we found a 20% reduction in molecular weight at 6 months. Arterial pressure and blood flow might possibly affect the degradation and healing process. The former may cause deterioration of structural integrity by mechanical forces, leading to dilatation, turbulent flow, and/or thrombosis, and the latter may wash out acidic degradation products, enhancing the cellular infiltration and angiogenesis. 13 Implanting PCL grafts into rat abdominal aorta resulted in deeper transmural cellular infiltration composed of macrophages, fibroblasts, and accompanying new capillaries, leveling off at 12 weeks after implantation. This cellular infiltration, accompanied by a monolayer of giant cells on the adventitial surface, which is part of chronic foreign body reaction, played a role in the degradation process soon after implantation and became clearly visible after 12 weeks ( Figure 6 ). Obviously, PCL grafts were only partially degraded after 24 weeks. However, our aim was not to demonstrate the full degradability of PCL grafts but to evaluate their degradation and healing characteristics over time under dynamic in vivo conditions. In our study, the slower degradation rate of PCL grafts, which is preferable to maintain the functionality of the graft during the graft healing period, may be due to the use of higher-M w and -M n PCL.
Despite the favorable characteristics discussed above, it appears that chondroid metaplasia is the major drawback of these PCL grafts. Vascular smooth muscle cells have the potential of modification from a differentiated "contractile" phenotype to a dedifferentiated "synthetic" phenotype at sites of vessel injury or atherosclerosis, 27 where some hypoxia does exist. 28 Local hypoxia stimulates the overexpression of transforming growth factor-␤ 1 from the vascular smooth muscle cells and/or endothelium, which may induce chondroid metaplasia formation in the intima of the arterial wall. 29 We observed severe chondroid metaplasia in the neointima of our PCL grafts at 6, 12, and 18 weeks. These metaplastic areas were replaced by calcifications at 24 weeks. Although the mechanism is not yet clear, we believe that the local hypoxia accompanied by acidic degradation products trig- gered some pathways as a local response and stimulated the expression of growth factors such as transforming growth factor-␤ 1 , leading to chondroid metaplastic degeneration.
The main limitation of our study was the small number of subjects at each time point and thus the limited statistical power. This was a consequence of the "3R principle" (reduce, refine, replace) in the animal experiments. However, the total number of rats was 15 per group, giving us the possibility of following up our end points (ie, endothelial coverage, neointima formation) longitudinally for up to 6 months and reaching statistical significance between nondegradable and degradable vascular grafts.
Conclusions
To the best of our knowledge, no data exist on the degradation and healing characteristics of PCL prostheses implanted into arterial circulation. In our experimental study with a 6-month follow-up, we found resistance to structural deterioration despite degradation and favorable graft healing characteristics, especially faster endothelialization. Thus, we hypothesize that PCL grafts may provide better patency rates than ePTFE grafts in revascularization procedures on small vessels. However, this has to be proven in large animal studies with longer follow-up before any clinical use. Further evaluation of degradation and graft healing characteristics, as well as preclusion of chondroid metaplastic degeneration, may potentially lead to clinical use of such biodegradable grafts for revascularization procedures in the future. 
